Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model
Alison Han(National Institutes of Health), Matthew J. Memoli(National Institutes of Health), Jerald Sadoff(University of Maryland, Baltimore), Amy Lwin(Janssen (Netherlands)), Yongli Xiao(National Institutes of Health), Keith Lumbard, Adriana Cervantes-Medina(National Institutes of Health), Jeffery K. Taubenberger(National Institutes of Health), Holly Ann Baus(National Institutes of Health), Sally Hunsberger(National Institute of Allergy and Infectious Diseases), Rani Athota(National Institutes of Health), Susan Reed(National Institutes of Health), Lindsay Czajkowski(National Institutes of Health), Monica Gouzoulis(National Institutes of Health), Luz Angela Rosas(National Institutes of Health)
Cited by 53
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin
|New England Journal of Medicine|1991|1.6k
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
|New England Journal of Medicine|1996|1.3k
Characterization of the 1918 influenza virus polymerase genes
|Nature|2005|1.1k
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
|Critical Care Medicine|1997|863